Also trades as: AUP.TO (TSX) · $vol 4M
AUPH NASDAQ
Aurinia Pharmaceuticals Inc.
1W: +3.0%
1M: +4.4%
3M: +13.6%
YTD: +12.4%
1Y: +45.1%
3Y: +130.0%
5Y: -13.4%
$17.25
+0.21 (+1.23%)
Weekly Expected Move ±3.3%
$16
$16
$17
$17
$18
Credit Risk of going bust: lower than 86% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.04 (down 99.8%), Aurinia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $60.4M against a stock market value of $2.30B.
Distance to default 11.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.2M (short-term plus half of long-term), stock volatility 37.4%; Altman Z'' 6.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $60.4M against a stock market value of $2.30B.
Distance to default 11.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.2M (short-term plus half of long-term), stock volatility 37.4%; Altman Z'' 6.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships6
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-08-17
Earliest Filing
2026-04-03
Latest Filing
partner: 5
target: 1
Counterparties (Filed by AUPH)
6 relationshipsCompanies named in AUPH's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kezar Life Sciences, Inc. | KZR | target | Target company in the proposed merger agreement with Aurinia Pharma U.S., Inc. | 2026-04-03 | View |
| Enodia Therapeutics SAS | — | partner | Counterparty to an existing Asset Purchase Agreement referenced in the Contingent Value Rights Agreement. | 2026-04-03 | View |
| Everest Medicines II (HK) Limited | — | partner | Counterparty to an existing Collaboration and License Agreement referenced in the Contingent Value Rights Agreement. | 2026-04-03 | View |
| MKT Capital Ltd. | — | partner | Entered into a cooperation agreement with Aurinia Pharmaceuticals Inc. | 2023-09-21 | View |
| MKT Tactical Fund, SP | — | partner | Entered into a cooperation agreement with Aurinia Pharmaceuticals Inc. | 2023-09-21 | View |
| Riptide Bioscience, Inc. | — | partner | Global licensing and research agreement for AUR300 peptide therapeutic | 2021-08-17 | View |
Mentioned As Counterparty
1 mentionsOther companies that named AUPH in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-19 | Other Events | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-04 | Shareholder Vote; Exhibits | View | |
| 2026-05-11 | Acquisition/Disposition; Exhibits | Acquisition | View |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-03 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-03-23 | Officer/Director Change; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition | View | |
| 2025-11-04 | Results of Operations and Financial Condition | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-30 | Other Events | View | |
| 2025-05-15 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-05-12 | Results of Operations and Financial Condition | View | |
| 2025-02-27 | Results of Operations and Financial Condition | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; De | View | |
| 2024-09-12 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2024-06-14 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2024-05-02 | Creation of Direct Financial Obligation; Financial Statements and Exhibits | View | |
| 2024-02-29 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-02-15 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; Ot | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR